Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans
Stopped In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023.
Conditions
- Cannabis
- Pain
- Tolerance
- Hyperalgesia
Interventions
- DRUG: Active Cannabis
- DRUG: Placebo Cannabis
Sponsor
New York State Psychiatric Institute
Collaborators